

Claims

What we claim is:

1. A composition comprising a biodegradable polymer having a ligand attached thereto, and wherein said ligand is attached to said biodegradable polymer using a biological recognition event.
2. A composition comprising a biomaterial architecture having a ligand attached thereto through a biological recognition event, and wherein said biological recognition event is further characterized in that it involves an anchor-adapter-tag unit, whereby said anchor is attached to the biomaterial architecture and said tag is attached to the ligand, and said adapter is capable of binding to both the anchor and the tag to effect the biological recognition event.
3. The composition of claim 2, wherein said anchor-adapter-tag unit is a three-component system.
4. The composition of claim 2, wherein said anchor-adapter-tag unit is a two-component system, whereby the anchor and adapter functionalities are provided by one molecule capable of effecting interaction with the tag unit, and an anchor-tag system is generated.
5. The composition of claim 2, wherein said anchor-adapter-tag unit is a two-component system, whereby the adapter and tag functionalities are provided by one molecule capable of effecting interaction with the adapter unit, and an anchor-tag system is generated.
6. The composition of claim 2, wherein the anchor and tag independently comprise any biologically relevant molecule capable of being incorporated into the biomaterial architecture and

1 the desired ligand, and wherein the adapter comprises any biologically relevant molecule capable
2 of binding to both the anchor and tag moieties to generate a biomolecular interaction.

3
4 7. The composition of claim 2, wherein said biomaterial architecture comprises a
5 biodegradable polymer.

6
7 8. The composition of claim 2, wherein said anchor is incorporated into the polymer during
polymer synthesis.

8
9 9. The composition of claim 2, wherein said polymer is PLA-PEG.

10
11
12 10. The composition of claim 2, wherein said biodegradable polymer is selected from the
13 group consisting of polymers of poly(hydroxy acids), polyanhydrides, polyorthoesters,
14 polyphosphazenes, polyphosphates, polycaprolactone, polyhydroxybutyrates, polyesters,
15 polyamides, polysaccharides, polyproteins, copolymers or blends thereof.

16
17 11. The composition of claim 2, wherein the anchor and tag comprise biotin and the adapter
18 comprises avidin or streptavidin.

19
20 12. The composition of claim 2, wherein the anchor and tag comprise the same or different
21 hapten, and the adapter comprises an antibody having the required specificity for the hapten(s).

22
23 13. The composition of claim 2, wherein said ligand comprises a biologically relevant
24 compound selected from the group consisting of peptide, protein, carbohydrate, nucleic acid,
25 lipid, polysaccharide, and combinations thereof.

26
27 14. The composition of claim 4, wherein the tag comprises a hapten and the anchor
28 comprises an antibody having the required specificity for the hapten.

1 15. The composition of claim 4, wherein the anchor comprises avidin and the tag comprises
2 biotin.

3
4 16. The composition of claim 5, wherein the anchor comprises a hapten and the tag
5 comprises an antibody having the required specificity for the hapten.

6
7 17. The composition of claim 5, wherein the anchor comprises biotin and the tag comprises
8 avidin.

9
10 *Sub 18* 18. A method for synthesizing a biomaterial architecture having an anchor associated
11 therewith comprising:

12 providing a solution of a biodegradable polymeric material, wherein said polymeric
13 material is capable of having an anchor moiety associated therewith and wherein said polymeric
14 material has at least one functionality capable of further polymerization;

15 contacting said solution with an anchor moiety capable of associating with said polymeric
16 material; and

17 subjecting said polymeric material having an anchor associated therewith to conditions
18 capable of effecting further polymerization at a desired functionality to yield a desired polymeric
19 material.

20
21 19. The method of claim 18, wherein said biodegradable polymeric material comprises α -
22 amine ω -hydroxy poly(ethylene glycol), and wherein this material having an anchor associated
23 therewith is further polymerized at the lactide functionality to generate a PLA (poly (lactic
24 acid))-PEG block copolymer having an anchor associated therewith.

25
26 20. The method of claim 18 or 19, wherein said anchor moiety comprises biotin.

27
28 21. The method of claim 18 or 19, wherein said anchor moiety comprises avidin.

1 22. The method of claim 18 or 19, wherein said anchor moiety comprises an antibody or
2 antibody fragment.

3
4 23. The method of claim 18 or 19, wherein said anchor moiety comprises a hapten.

5
6 24. A method for the modification of a biomaterial architecture comprising:
7 providing a biomaterial architecture, having an anchor attached thereto or incorporated
8 therein;
9 contacting said biomaterial-anchor moiety with an adapter moiety; and
10 contacting said biomaterial-anchor-adapter moiety with a desired ligand having a tag
11 incorporated therein to produce a biomaterial-anchor-adapter-tag-ligand moiety.

12
13 25. The method of claim 24, wherein the anchor and tag independently comprise any
14 biologically relevant molecule capable of being incorporated into the biomaterial architecture and
15 the desired ligand, and wherein the adapter comprises any biologically relevant molecule capable
16 of binding to both the anchor and tag moieties.

17
18 26. The method of claim 24, wherein said biomaterial architecture comprises a biodegradable
19 polymer.

20
21 27. The method of claim 24, wherein said anchor is incorporated into the polymer during
22 polymer synthesis.

23
24 28. The method of claim 27, wherein said polymer is preferably PLA-PEG.

25
26 29. The method of claim 24, wherein said biodegradable polymer is selected from the group
27 consisting of polymers of polyhydroxy acids, polyanhydrides, polyorthoesters,

1 polyphosphazenes, polyphosphates, polycaprolactone, polyhydroxybutyrates, polyesters,
2 polyamides, polysaccharides, polyproteins, and copolymers and blends thereof.

3
4 30. The method of claim 24, wherein the anchor and tag comprise biotin and the adapter
5 comprises avidin or streptavidin.

6
7 31. The method of claim 24, wherein the anchor and tag comprise the same or different
8 haptens, and the adapter comprises an antibody having the required specificity for the haptens(s).

9
10 Sub
11 an
12 32. The method of claim 24, wherein said ligand comprises a biologically relevant compound
13 selected from the group consisting of peptide, protein, carbohydrate, nucleic acid, lipid,
14 polysaccharide, and combinations thereof.

15
16 33. A method for the modification of a biomaterial architecture comprising:
17 providing a biomaterial architecture, having an anchor attached thereto or incorporated
18 therein; and
19 contacting said biomaterial-anchor moiety with a desired ligand having a tag incorporated
20 therein to produce a biomaterial-anchor-tag-ligand moiety.

21 Sub
22 34. The method of claim 33, wherein the anchor and tag independently comprise any
23 biologically relevant molecule capable of being incorporated into the biomaterial architecture and
24 the desired ligand, and effecting a biomolecular interaction between the anchor and tag.

25 35. The method of claim 33, wherein said biomaterial architecture comprises a biodegradable
26 polymer.

27 36. The method of claim 33, wherein said anchor is incorporated into the polymer during
28 polymer synthesis.

1 37. The method of claim 36, wherein said polymer is preferably PLA-PEG.

2
3 38. The method of claim 33, wherein said biodegradable polymer is selected from the group
4 consisting of polymers of polyhydroxy acids, polyanhydrides, polyorthoesters,
5 polyphosphazenes, polyphosphates, polycaprolactone, polyhydroxybutyrates, polyesters,
6 polyamides, polysaccharides, polyproteins, and copolymers and blends thereof.

7
8 39. The method of claim 33, wherein the anchor comprises biotin and the tag comprises
9 avidin or streptavidin.

10
11 40 The method of claim 33, wherein the anchor comprises avidin or streptavidin and the tag
12 comprises biotin.

13
14 41. The method of claim 33, wherein the anchor comprises a hapten, and the tag comprises
15 an antibody having the required specificity for the hapten.

16
17 42. The method of claim 33, wherein the tag comprises a hapten, and the anchor comprises
18 an antibody having the required specificity for the hapten.

19
20 43. The method of claim 33, wherein said ligand comprises a biologically relevant compound
21 selected from the group consisting of peptide, protein, carbohydrate, nucleic acid, lipid,
22 polysaccharide, and combinations thereof.

23
24 44. A method for tissue engineering comprising:
25 providing a scaffold having a biological ligand attached thereto, wherein said ligand is
26 attached by a biomolecular interaction;
27 contacting said scaffold with cells, wherein said cells interact specifically with the ligand
28 attached to the scaffold;

1 promoting cell growth and/or differentiation to generate tissue; and
2 implanting said tissue.

3
4 Sub
5 45. The method of claim 44, wherein said biomolecular interaction is characterized in that it
6 involves an anchor-adapter-tag unit, whereby said anchor is attached to the biomaterial
7 architecture and said tag is attached to the ligand, and said adapter is capable of binding to both
8 the anchor and the tag.

9 46. The method of claim 44, wherein the anchor and tag independently comprise any
10 biologically relevant molecule capable of being incorporated into the biomaterial architecture and
11 the desired ligand, and wherein the adapter comprises any biologically relevant molecule capable
12 of binding to both the anchor and tag moieties to generate a biomolecular interaction.

13
14 47. The method of claim 44, wherein said biomolecular interaction is characterized in that it
15 involves an anchor-tag unit, whereby said anchor is attached to the biomaterial architecture and
16 said tag is attached to the ligand and wherein either the anchor or the tag is capable of effecting a
17 biomolecular interaction between the anchor and the tag.

18 Sub
19 48. The method of claim 47, wherein the anchor and tag comprise any biologically relevant
20 molecule capable of being incorporated into the biomaterial architecture and the desired ligand,
21 and wherein a biomolecular interaction is effected between the anchor and the tag.

22
23 49. The method of claim 44, wherein said scaffold comprises a biodegradable polymer.

24
25 50. The method of claim 45 or 47, wherein said anchor is incorporated into the polymer
26 during polymer synthesis.

27
28 51. The method of claim 50, wherein said polymer is PLA-PEG.

1 52. The method of claim 44 wherein promoting cell growth and/or differentiation comprises
2 seeding cells in a bioreactor.

3
4 53. The method of claim 44, wherein implanting said tissue comprises implanting tissue still
5 attached to the scaffold.

6
7 54. The method of claim 44, wherein implanting said tissue comprises degrading the scaffold
8 and implanting the tissue without the scaffold.

9
10 55. A method for site specific delivery of therapeutic agents comprising:
11 providing a composition further comprising:

12 a biomaterial architecture, wherein said architecture has a biological ligand
13 attached thereto by a biomolecular interaction, and

14 a therapeutic agent associated therewith; and

15 contacting said composition with cells, wherein the ligand attached to the biomaterial
16 architecture interacts with the cells to effect site specific delivery of the therapeutic agent to the
17 cells.

18
19 56. The method of claim 55, wherein said biomolecular interaction is further characterized in
20 that it involves an anchor-adapter-tag unit, whereby said anchor is attached to the biomaterial
21 architecture and wherein said tag is attached to the ligand, and said adapter is capable of binding
22 to both the anchor and the tag.

23
24 57. The method of claim 56, wherein the anchor and tag independently comprise any
25 biologically relevant molecule capable of being incorporated into the biomaterial architecture and
26 the desired ligand, and wherein the adapter comprises any biologically relevant molecule capable
27 of binding to both the anchor and tag moieties to generate a biomolecular interaction.
28

1 58. The method of claim 55, wherein said biomolecular interaction is characterized in that it
2 involves an anchor-tag unit, whereby said anchor is attached to the biomaterial architecture and
3 said tag is attached to the ligand and wherein either the anchor or the tag is capable of effecting a
4 biomolecular interaction between the anchor and the tag.
5

6 59. The method of claim 58, wherein the anchor and tag comprise any biologically relevant
7 molecule capable of being incorporated into the biomaterial architecture and the desired ligand,
8 and wherein a biomolecular interaction is effected between the anchor and the tag.
9

10 60. The method of claim 55, wherein said biomaterial architecture comprises a biodegradable
11 polymer.
12

13 61. The method of claim 56 or 58, wherein said anchor is incorporated into the polymer
14 during polymer synthesis.
15

16 62. The method of claim 61, wherein said polymer is PLA-PEG.
17

18 63. The method of claim 55, wherein said therapeutic agent is selected from the group
19 consisting of anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants,
20 anti-viral substances, enzyme, inhibitors, neurotoxins, opioids, hypnotics, antihistamines,
21 lubricants, tranquilizers, anti-convulsants, muscle relaxants, anti-Parkinson's substances, anti-
22 spasmodics, muscle contractants, miotics, anti-cholinergics, anti-glaucoma compounds, anti-
23 parasite compounds, anti-protozoal compounds, anti-hypertensives, analgesics, anti-pyretics,
24 anti-inflammatory agents, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-
25 psychotic substances, anti-emetics, imaging agents, specific targeting agents, neurotransmitters,
26 proteins, cell response modifiers, vaccines, ribozymes, anti-sense agents, cytokines,
27 immunotoxins, radiosensitizers, anti-edema agents, RNA, and combinations thereof.
28